BB BIOTECH VENTURES III is dedicated to investing in emerging healthcare companies and will primarily focus on product-driven, clinical-stage drug development and medical device companies. The fund will also consider cash-flow-positive businesses requiring growth capital, or earlier-stage technology platform companies. The best opportunities will be chosen without a fixed geographic allocation.

Typical target company profiles

• Human Proof-of-Concept Trials
  Getting compounds through proof-of-concept (clinical phase II)
• Registration Trials/ Marketing
  Taking products from phase II to market with own sales infrastructure
• Businesses/ Growth Capital
  Expansion of running businesses in companies with positive operating cash flow
• IP protected Technologies
  Companies with IND enabling technologies with unique IP position

 

The objective is to achieve superior returns by leveraging the long-standing investment expertise, sector knowledge, network and hands-on experience of the investment advisors and the Bellevue Group.